These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 18848313)

  • 21. Immunotherapy of Guillain-Barré syndrome.
    Liu S; Dong C; Ubogu EE
    Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Guillain-Barré syndrome.
    McNair ND
    J Infus Nurs; 2013; 36(6):397-400. PubMed ID: 24202119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatments and outcome predictors in Guillain-Barré syndrome].
    Uchibori A; Chiba A
    Nihon Rinsho; 2013 May; 71(5):845-9. PubMed ID: 23777092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
    van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
    J Peripher Nerv Syst; 2023 Dec; 28(4):535-563. PubMed ID: 37814551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
    van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
    Eur J Neurol; 2023 Dec; 30(12):3646-3674. PubMed ID: 37814552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
    Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
    BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guillain-Barré syndrome--a patient guide and nursing resource.
    Kehoe M
    Axone; 2001 Jun; 22(4):16-24. PubMed ID: 14621501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh.
    Islam Z; Jacobs BC; van Belkum A; Mohammad QD; Islam MB; Herbrink P; Diorditsa S; Luby SP; Talukder KA; Endtz HP
    Neurology; 2010 Feb; 74(7):581-7. PubMed ID: 20157160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Guillain-Barré syndrome in childhood].
    Kollár K; Liptai Z; Rosdy B; Móser J
    Ideggyogy Sz; 2009 Nov; 62(11-12):399-404. PubMed ID: 20025130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guillain-Barré syndrome following chickenpox: a case series.
    Tatarelli P; Garnero M; Del Bono V; Camera M; Schenone A; Grandis M; Benedetti L; Viscoli C
    Int J Neurosci; 2016; 126(5):478-9. PubMed ID: 26000930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.
    Yuki N
    Lancet Infect Dis; 2001 Aug; 1(1):29-37. PubMed ID: 11871407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guillain-Barré syndrome as leading manifestation of graft-versus-host disease in an allogeneic bone marrow transplanted patient.
    Thöne J; Lamprecht S; Hohaus A; Erbguth F; Bickel A
    J Neurol Sci; 2010 May; 292(1-2):114-6. PubMed ID: 20163810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic Factors in Guillain-Barré Syndrome].
    Kaida K
    Brain Nerve; 2015 Nov; 67(11):1411-9. PubMed ID: 26560956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Guillain-Barré Syndrome].
    Nomura K
    Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axonal Guillain-Barré syndrome: concepts and controversies.
    Kuwabara S; Yuki N
    Lancet Neurol; 2013 Dec; 12(12):1180-8. PubMed ID: 24229616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
    Dada MA; Kaplan AA
    Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [History of Guillain-Barré Syndrome].
    Kusunoki S
    Brain Nerve; 2015 Nov; 67(11):1295-303. PubMed ID: 26560944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Siglec-7 specifically recognizes Campylobacter jejuni strains associated with oculomotor weakness in Guillain-Barré syndrome and Miller Fisher syndrome.
    Heikema AP; Jacobs BC; Horst-Kreft D; Huizinga R; Kuijf ML; Endtz HP; Samsom JN; van Wamel WJ
    Clin Microbiol Infect; 2013 Feb; 19(2):E106-12. PubMed ID: 23173866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guillain-Barré syndrome.
    Walling AD; Dickson G
    Am Fam Physician; 2013 Feb; 87(3):191-7. PubMed ID: 23418763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of Guillain-Barré syndrome (GBS) in China: a 10-year comprehensive overview.
    Song Y; Zheng X; Fang Y; Liu S; Liu K; Zhu J; Wu X
    Rev Neurosci; 2023 Dec; 34(8):869-897. PubMed ID: 37145885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.